ESR1 and breast carcinoma: Preclinical work has shown that anti‐estrogen‐resistant ER+ breast cancer cell lines and xenografts can become sensitized to anti‐estrogen withdrawal and estrogen treatment (reviewed by Jordan et al., 2011).